3D biofabrication

R&D

pharmaphorum in conversation with Immortal Dragons and Frontier Bio about 3D tissue biofabrication and the race for healthy longevity.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.